Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/24/2005US20050065186 Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
03/24/2005US20050065185 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
03/24/2005US20050065179 Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments
03/24/2005US20050065178 Substituted diazabicycloakane derivatives
03/24/2005US20050065170 Compounds
03/24/2005US20050065168 Dissolving in solvent; precipitation; isolation; sleep disorders; antiepileptic agents; muscle relaxants
03/24/2005US20050065162 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
03/24/2005US20050065157 Carbazole derivatives and their use as npy5 receptor antagonists
03/24/2005US20050065148 Dipeptidyl peptidase inhibitors
03/24/2005US20050065146 Cognition activators; neurodegenerative diseases; anxiolytic agents;psychological disorders; alzheimer's disease; Huntington's disease; antiischemic agents; antiepileptic agenst
03/24/2005US20050065140 Antidepressant; side effect reduction
03/24/2005US20050065134 2-aklylidene-19-nor-vitamin D derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
03/24/2005US20050065118 Compound containing 1,3,4-thiadiazole group; anticancer agents; autoimmune disease; antidiabetic agents
03/24/2005US20050065116 Thiazolopyrimidines useful as TNFalpha inhibitors
03/24/2005US20050065110 Synergistic mixture; antioxidant; cardiovascular disorders; antidiabetic agents
03/24/2005US20050065102 Medicinal compositions
03/24/2005US20050065094 Synergistic mixture with other drug; side effect reduction
03/24/2005US20050065093 Inhibitors of the ICE/ced-3 family of cysteine proteases
03/24/2005US20050065085 Tissue disorders in response to injuries with administering polypeptidesand antibodies with gene delivery for inflammation such as arthritis
03/24/2005US20050065082 C-jun phosphorylation inhibitors
03/24/2005US20050064586 Somatic cell derived embryonic stem cells and its differentiated cells
03/24/2005US20050064543 Secreted proteins
03/24/2005US20050064534 Using microscopic systems to monitoring f-actin and myosin activity in cells; monitoring biopolymer transfer between membrane walls
03/24/2005US20050064530 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
03/24/2005US20050064491 Transport protein for use as tool in identifying modulator for treatment of sleep, nervous suystem, anixety, eating, cardiovascular and pain disordere
03/24/2005US20050064458 Nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatnment of cell proliferative, nervous system, metabolic and inflammatory disorders
03/24/2005US20050064404 Regulation of human serotonin-like g protein-coupled receptor
03/24/2005US20050063965 Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
03/24/2005US20050063943 Conjugated of hydroxyalkyl starch and an active agent
03/24/2005US20050063940 Use of (poly)ethoxylated fatty acid glycerides for enhancing bioadhesion of a liquid pharmaceutical applied to a mucous membrane; use delivering active agents to plants, fish gills
03/24/2005US20050063909 Drug and adverse-effect agent coated with inner acid-soluble layer and outer base-soluble layer; sustained release; multilayer tablets; for treatment of pain with opiod analgesics
03/24/2005DE10338544A1 Film for buccal administration comprises galanthamine and polymer layer, useful for treating diseases associated with defective acetylcholine-mediated signal transduction and/or dysregulation of neuronal nicotinic receptors
03/24/2005DE10338174A1 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit Transdermal drug formulations with drug combinations for the treatment of Parkinson's disease
03/24/2005CA2539454A1 Preventive for cerebral stroke recurrence
03/24/2005CA2539033A1 Treatment of disease or injury of the nervous system with fty720
03/24/2005CA2538910A1 Use of known active ingredients as radical scavengers
03/24/2005CA2538412A1 Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
03/24/2005CA2538245A1 Oligonucleotides targeting prion diseases
03/24/2005CA2538231A1 A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration
03/24/2005CA2538220A1 Use of antibody
03/24/2005CA2536107A1 Substituted piperazines of azepines, oxazepines, and thiazepines
03/23/2005EP1517144A2 Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
03/23/2005EP1516926A1 Process for producing nerve cells
03/23/2005EP1516871A1 Benzoindoline derivatives with adrenergic activity
03/23/2005EP1516625A1 Uses of neuronal channels-forming pannexins for therapy and diagnosis in mammals
03/23/2005EP1516064A2 Methods of using 46828, a human acyl-coa synthetase
03/23/2005EP1516047A1 Purified pkb ser 473 kinase and uses thereof
03/23/2005EP1515978A1 Sulfur-containing phospholipid derivatives
03/23/2005EP1515975A1 Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
03/23/2005EP1515974A2 Novel maxi-k channel blockers, methods of use and process for making the same
03/23/2005EP1515968A2 Quinuclidine derivatives and pharmaceutical compositions containing the same
03/23/2005EP1515967A1 2-heteroaryl carboxamides
03/23/2005EP1515961A1 N,n-disubstituted diazocycloalkanes useful for the treatment of cns disorders due to serotonergic dysfunction
03/23/2005EP1515960A1 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same
03/23/2005EP1515959A1 Pharmaceutical salts of reboxetine
03/23/2005EP1515953A2 Novel hexahydro-pyridazine-3-carbocylic acid hydrazide or hydrazone derivatives, combinatorial libraries containing same, use thereof as medicines, pharmaceutical compositions containing same and methods for preparing same
03/23/2005EP1515947A1 Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
03/23/2005EP1515944A1 Aspartyl protease inhibitors
03/23/2005EP1515942A1 Carboxamides derivatives
03/23/2005EP1515926A2 Fluorobenzamides suitable for the treatment of alzheimer's disease or senile dementia
03/23/2005EP1515753A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
03/23/2005EP1515732A1 Cerebral protection with a gas comprising xenon
03/23/2005EP1515731A1 Anti-spasmodic comprising xenon
03/23/2005EP1515730A1 Novel maxi-k channel blockers, methods of use and process for making the same
03/23/2005EP1515722A2 Ophthalmic compositions for treating ocular hypertension
03/23/2005EP1515721A1 Ophthalmic compositions for treating ocular hypertension
03/23/2005EP1515719A2 Enhancing treatment of mdr cancer with adenosine a3 antagonists
03/23/2005EP1515718A2 Modulation of activation of glucocorticoid receptors by breakdown products of glucocorticoids
03/23/2005EP1515709A2 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
03/23/2005EP1515708A1 Combinations of pde-v inhibitors and nk1 antagonists for the treatment of depression
03/23/2005EP1515702A1 Abuse-protected administration form
03/23/2005EP1383579B1 Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
03/23/2005EP1280528B1 R-eliprodil for treating glaucoma
03/23/2005EP1272218B1 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
03/23/2005EP1089733B1 Use of optically pure (+)-norcisapride for treating irritable bowel syndrome
03/23/2005EP1032398B1 Treating postmenopausal women using ultra-low doses of estrogen
03/23/2005EP1027064B1 A process for the removal of undersired toxic alkaloids from plants or from vegetable preparations
03/23/2005EP0804613B1 Dap-2 tumor suppressor gene, protein encoded thereby and use of said gene and protein
03/23/2005EP0662092B1 Activity-dependent neurotrophic factor
03/23/2005EP0574579B1 Dna encoding a human 5-ht 1f receptor and uses thereof
03/23/2005CN1599745A Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
03/23/2005CN1599741A Thioether substituted imidazoquinolines
03/23/2005CN1599740A Amide substituted imidazopyridines
03/23/2005CN1599739A Sulfonamido substituted imidazopyridines
03/23/2005CN1599738A Urea substituted imidazopyridines
03/23/2005CN1599737A Ring fused pyrazole derivatives
03/23/2005CN1599734A 3, 4-di-substituted maleimide compounds as CXC-chemokine receptor antagonists
03/23/2005CN1599730A Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
03/23/2005CN1599726A Pyrimidine compounds
03/23/2005CN1599724A Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
03/23/2005CN1599722A 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
03/23/2005CN1599718A Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
03/23/2005CN1599715A Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
03/23/2005CN1599618A Stabilization of hypoxia inducible factor (HIF) alpha
03/23/2005CN1599614A Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
03/23/2005CN1599613A Combinations for the treatment of immunoinflammatory disorders
03/23/2005CN1599608A Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes
03/23/2005CN1599607A Carbinols for the treatment of neuropathic dysfunction
03/23/2005CN1599604A Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
03/23/2005CN1597677A Compounds and methods for modulation of estrogen receptors
1 ... 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 ... 1833